ArticleBMJ open2024

Protocol for a multicentric, double-blind, randomised controlled trial of hyperbaric oxygen therapy (HBOT) versus sham for treating vaso-occlusive crisis (VOC) in sickle cell disease (SCD) in patients aged 8 years or older (HBOT-SCD study).

Jerome Stirnemann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.